UK Launches Major Prostate Cancer Screening Trial to Reduce Deaths by 40%

The Transform trial, backed by £42 million, will test new screening methods to improve early detection and minimize unnecessary treatments.

The Transform trial aims to revolutionize prostate cancer screening by testing combinations of PSA tests, genetic testing, and high-speed MRI scans.
Initial phase to involve 12,500 men, with results expected in three years; subsequent phase to include up to 300,000 participants.
Researchers focus on reducing prostate cancer deaths and the harm caused by outdated screening methods.
Significant emphasis on including diverse populations, with at least one in ten participants being black men, who are at higher risk.
The trial could set new global standards for prostate cancer screening, potentially saving tens of thousands of lives annually.